| Page 1294 | Kisaco Research
 

C. Vivek Lal

Founder & CEO
ResBiotic

C. Vivek Lal

Founder & CEO
ResBiotic

C. Vivek Lal

Founder & CEO
ResBiotic
 

Karen Miller

Senior Scientist
BioTheryX

Initial introduction to molecular glues during tenure at Celgene from 2010-2015 where she was a key member on the IMiD “mechanism of action” discovery team. Work here directly contributed to the clinical development of pomalidomide and downstream mechanistic discovery of IMiDs including in-house identification of Ikaros, Aiolos, and GSPT1 as neosubstrates of various IMiD molecules.  Subsequently, left Celgene to obtain her PhD from The Scripps Research Institute under the tutelage of Dr.

Karen Miller

Senior Scientist
BioTheryX

Karen Miller

Senior Scientist
BioTheryX

Initial introduction to molecular glues during tenure at Celgene from 2010-2015 where she was a key member on the IMiD “mechanism of action” discovery team. Work here directly contributed to the clinical development of pomalidomide and downstream mechanistic discovery of IMiDs including in-house identification of Ikaros, Aiolos, and GSPT1 as neosubstrates of various IMiD molecules.  Subsequently, left Celgene to obtain her PhD from The Scripps Research Institute under the tutelage of Dr. Michael McHeyzer-Williams, focusing on adaptive immunity through germinal center formation and evolution. Following completion of her degree in 2021, she returned to the TPD space, moving to Biotheryx where she is currently the biology lead for both the BTX-1188 and Neosubstrate Discovery projects.

 

Katie Kam

CEO & Co- Founder
BioBQ

Katie Kam

CEO & Co- Founder
BioBQ

Katie Kam

CEO & Co- Founder
BioBQ
 

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS

Ingrid E. Wertz is the Executive Director of the Protein Homeostasis Center of Excellence at Bristol Myers Squibb. She obtained her undergraduate degree in Molecular and Cellular Biology from the University of California at Berkeley, performed her graduate studies at Genentech via an NIH Biotechnology Training Grant from U.C. Davis, and received her M.D. from Washington University in St. Louis as a Medical Scientist Training Program fellow. Dr. Wertz was a recipient of the Harold M. Weintraub Graduate Student Award. Prior to joining BMS in May of 2021, Dr.

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS

Ingrid Wertz

Executive Director, Protein Homeostasis Center of Excellence
BMS

Ingrid E. Wertz is the Executive Director of the Protein Homeostasis Center of Excellence at Bristol Myers Squibb. She obtained her undergraduate degree in Molecular and Cellular Biology from the University of California at Berkeley, performed her graduate studies at Genentech via an NIH Biotechnology Training Grant from U.C. Davis, and received her M.D. from Washington University in St. Louis as a Medical Scientist Training Program fellow. Dr. Wertz was a recipient of the Harold M. Weintraub Graduate Student Award. Prior to joining BMS in May of 2021, Dr. Wertz was a Principal Scientist at Genentech. There she served as the Biology Lead for BCL-2 family antagonists that contributed to venetoclax, she was the initial Biology Lead for the selective estrogen receptor degrader (SERDs) program that contributed to giredistrant, she led USP7 inhibitor drug discovery teams, and co-initiated and led the Genentech Degrader Platform. Dr. Wertz’s research is primarily focused on elucidating the molecular mechanisms of therapeutic compounds and co-opting the Ubiquitin System for therapeutic benefit.

 

Ian Mackay

Apparo

Ian Mackay

Apparo

Ian Mackay

Apparo
 

Vincent Kitrattragarn

Founder/ CEO
Dang

Vincent Kitrattragarn

Founder/ CEO
Dang

Vincent Kitrattragarn

Founder/ CEO
Dang

This presentation, by the RISC-V founder, will highlight how RISC-V and vector compute are gaining momentum with AI and ML and computer vision and how it addresses challenges like managing power consumption, extra data movement, the need for multiple libraries, and issues with generational incompatibility. To solve these obstacles, many of the world’s largest data and device companies are turning to vector processing based on the RISC‑V Vector (RVV) 1.0 ISA.

Chip Design
Enterprise AI
ML at Scale
Novel AI Hardware
Hardware Engineering
Systems Engineering
Strategy

Author:

Krste Asanovic

Co-Founder & Chief Architect
SiFive

Krste is SiFive’s Chief Architect and a Co-Founder. He is also a Professor in the EECS Department at the University of California, Berkeley, where he also serves as Director of the ADEPT Lab. Krste leads the RISC‑V ISA project at Berkeley and is Chairman of the RISC‑V Foundation. He is an ACM Fellow and an IEEE Fellow. Krste received his PhD from UC Berkeley, and a BA in Electrical and Information Sciences from the University of Cambridge.

Krste Asanovic

Co-Founder & Chief Architect
SiFive

Krste is SiFive’s Chief Architect and a Co-Founder. He is also a Professor in the EECS Department at the University of California, Berkeley, where he also serves as Director of the ADEPT Lab. Krste leads the RISC‑V ISA project at Berkeley and is Chairman of the RISC‑V Foundation. He is an ACM Fellow and an IEEE Fellow. Krste received his PhD from UC Berkeley, and a BA in Electrical and Information Sciences from the University of Cambridge.